HTA and decision making in the reimbursement of medicines

05 Jul 2022

Vidya Breeveld-Dwarkasing Presentations

July 5, 2022 Vidya Breeveld-Dwarkasing

Is Pharma having a value conversation while Payers want a value demonstration?

On June 16 I held this presentation about the differences in perspectives between Pharma and Payers when appraising the value of innovative medicines at the 6th Pharma, Reimbursement & Market Access congres 2022 in Boston Massachusetts.

A very relevant discussion as the increasing introductions of precision medicines are introducing new complexities in health technology assessment creating an innovation paradox.

Companies planning to launch these products in the coming years face the challenge of having to place big bets on an uncertain future which requires rethinking of the critical capabilities needed at multiple levels in their organization.

Vidya Breeveld-Dwarkasing

Vidya started working as a pricing & reimbursement manager in Pharma in 2010, after a short one-year career as a regulatory affairs manager. Before that, as a trained veterinarian she had an academic career at the Utrecht University, Faculty of veterinary medicine. There she acquired a Ph.D. in Biomedical science while teaching obstetrics and gynecology in farm animals at the herd health department. During her years in Novartis, Abbvie, Sanofi Pasteur-MSD and most recent Sanofi, she acquired extensive experience in public affairs, pricing & market access, team management, incorporate initiatives, training & development, and stakeholder engagement. She is formally qualified to teach at the university level. That also helps her to deploy different training methodologies depending on the team composition and training goals. She is adept at developing access strategies and creating cross-functional alignment to successfully execute reimbursement procedures and product launches in complex circumstances. View all posts by Vidya Breeveld-Dwarkasing